Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-15
2007-05-15
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S469000, C548S484000, C548S486000, C548S511000
Reexamination Certificate
active
10464174
ABSTRACT:
A compound of the formulaor a pharmaceutically acceptable salt thereof, wherein:R1, R2, R3, R4, R5, R6, L1, L2, M, n, p, X, Y and Z are as described in the specification; pharmaceutical compositions thereof, methods of making said pharmaceutical compositions; and methods of use thereof.
REFERENCES:
patent: 4466965 (1984-08-01), Stout et al.
patent: 4567184 (1986-01-01), Musser et al.
patent: 5332820 (1994-07-01), Duncia et al.
patent: 5338753 (1994-08-01), Burstein et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5486525 (1996-01-01), Summers, Jr. et al.
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 5948777 (1999-09-01), Bender et al.
patent: 5990170 (1999-11-01), Della Valle et al.
patent: 6013648 (2000-01-01), Rinaldi et al.
patent: 6017919 (2000-01-01), Inaba et al.
patent: 19533644 (1995-09-01), None
patent: 0181568 (1986-05-01), None
patent: 0401030 (1990-12-01), None
patent: 0407217 (1991-01-01), None
patent: 1031571 (2000-08-01), None
patent: 1283039 (2003-02-01), None
patent: 06072979 (1994-03-01), None
patent: WO 93/21158 (1993-10-01), None
patent: WO 96/23783 (1996-08-01), None
patent: WO 97/03953 (1997-02-01), None
patent: WO 98/10763 (1998-03-01), None
patent: WO 98/31227 (1998-07-01), None
patent: WO 98/33769 (1998-08-01), None
patent: WO 98/41519 (1998-09-01), None
patent: WO 99/26612 (1999-06-01), None
patent: WO 99/36393 (1999-07-01), None
patent: WO 99/50245 (1999-10-01), None
patent: WO 00/06146 (2000-02-01), None
patent: WO 01/37826 (2001-05-01), None
patent: WO 01/44172 (2001-06-01), None
patent: WO 01/44239 (2001-06-01), None
patent: WO 01/64642 (2001-09-01), None
patent: WO 01/70753 (2001-09-01), None
patent: WO 01/74762 (2001-10-01), None
patent: WO 01/83460 (2001-11-01), None
patent: WO 02/062750 (2002-08-01), None
patent: WO 03/042174 (2003-05-01), None
M. Curtin et al., “Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists”, 41(1)J. Med. Chem.74-95 (1998).
G. Hartman et al., “4-Substituted Thiophene—and Furan—2-Sulfonamides as topical carbonic anhydrase inhibitors” 35(21)J. Med. Chem.3822-31 (1992).
G. Hartman et al., “Synthesis and derivatization of 4-(arylsulfonyl) thiophene—and—furan—2 sulfonamides”, 27(2)J. Heterocycl. Chem.127-34 (1990).
P. Cozzi et al., New N-(2-ethoxyethyl)-N-(4-phenoxybenzyl) dichloroacetamides as potent antiamoebic agents 18(3)Eur. J. Med. Chem.203-208 (1983).
U.S. Appl. No. 03/024,398, for “Cannabinoid Receptor Ligands”, filed Aug. 5, 2003.
U.S. Appl. No. 10/464,174, for “Cannabinoid Receptor Agonist”, filed Jun. 17, 2003.
R.G. Pertwee, “Pharmacology of Cannabinoid Receptor Ligands”, Curr. Med. Chem 6(8), (1999), 635-664.
T.W. Greene et al. Protective Groups in Organic Synthesis (1981), Wiley, New York.
T. Higuchi and V. Stella, Pro-drugs as Novel Drug Delivery Systems (1975) 14 of the A.C.S. Symposium Series.
Bio reversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press.
S. Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19.
P. Gould, “Salt Selection for Basic Drugs”, International J. of Pharmaceutics (1986) 33 201-217.
Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York.
International Search Report for PCT/US 03/19245.
European Patent Office Communication Pursuant to Article 96(2) EPC (dated Nov. 1, 2006)-4 Pages.
Kozlowski Joseph A.
Shankar Bandarpalle B.
Shih Neng-Yang
Tong Ling
Lee William Y.
Schering Corporation
Shameem Golam M. M.
LandOfFree
Cannabinoid receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cannabinoid receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cannabinoid receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3799111